Results 1 to 10 of about 29,611 (195)

Formulation, development and characterization of fosfomycin tromethamine pessaries for the treatment of vaginal infections [PDF]

open access: yesScientific Reports
Background The present study investigated the formulation, development, and characterization of Fosfomycin pessaries for the treatment of genitourinary tract infections. To achieve higher local concentration and to avoid the systemic exposure of the body
Mahboob Ul Haq   +5 more
doaj   +2 more sources

Fosfomycin: Pharmacological, Clinical and Future Perspectives

open access: yesAntibiotics, 2017
Fosfomycin is a bactericidal, low-molecular weight, broad-spectrum antibiotic, with putative activity against several bacteria, including multidrug-resistant Gram-negative bacteria, by irreversibly inhibiting an early stage in cell wall synthesis ...
Jacobus Burggraaf   +2 more
exaly   +3 more sources

Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae

open access: yesJournal of Global Antimicrobial Resistance, 2020
Objectives: Older antimicrobials such as fosfomycin are being considered as alternative agents in the treatment of drug-resistant organisms. However, there are limited data on the usefulness of fosfomycin against carbapenem-resistant Klebsiella ...
Peng Liu   +5 more
exaly   +3 more sources

Mutations of the Transporter Proteins GlpT and UhpT Confer Fosfomycin Resistance in Staphylococcus aureus

open access: yesFrontiers in Microbiology, 2017
With the increasing spread of methicillin-resistant Staphylococcus aureus worldwide, fosfomycin has begun to be used more often, either alone or in combination with other antibiotics, for treating methicillin-resistant S.
Xiaogang Xu, Minggui Wang
exaly   +3 more sources

Update on fosfomycin-modified genes in Enterobacteriaceae

open access: yesJournal of Microbiology, Immunology and Infection, 2019
The long-used antibiotic fosfomycin has recently been re-evaluated as a potential regimen for treating extended-spectrum β-lactamases (ESBLs) and carbapenem-resistant Enterobacteriaceae (CRE).
Tsung-Ying Yang   +2 more
exaly   +3 more sources

Fosfomycin [PDF]

open access: yesClinical Microbiology Reviews, 2016
SUMMARY The treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria.
Matthew E, Falagas   +3 more
  +5 more sources

Glucose-6-phosphate Reduces Fosfomycin Activity Against Stenotrophomonas maltophilia

open access: yesFrontiers in Microbiology, 2022
It is generally accepted that fosfomycin activity is higher in the presence of glucose-6-phosphate, since its inducible transporter UhpT is one of the gates for fosfomycin entry.
Teresa Gil-Gil   +2 more
doaj   +1 more source

Inactivation of ackA and pta Genes Reduces GlpT Expression and Susceptibility to Fosfomycin in Escherichia coli

open access: yesMicrobiology Spectrum, 2023
Fosfomycin is used to treat a variety of bacterial infections, including urinary tract infections caused by Escherichia coli. In recent years, quinolone-resistant and extended-spectrum β-lactamase (ESBL)-producing bacteria have been increasing.
Hidetada Hirakawa   +8 more
doaj   +1 more source

In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing Klebsiella pneumoniae Clinical Isolates

open access: yesAntibiotics, 2023
Fosfomycin disodium is a potential therapeutic option to manage difficult-to-treat infections, especially when combined with other antimicrobials. In this study, we evaluated the activity of fosfomycin in combination with meropenem or polymyxin B against
Aghata Cardoso da Silva Ribeiro   +7 more
doaj   +1 more source

Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem–Resistant Acinetobacter baumannii

open access: yesPharmaceuticals, 2021
The spread of multi-drug resistant (MDR) pathogens and the lagging pace in the development of novel chemotherapeutic agents warrant the use of combination therapy as a reliable, cost-effective interim option.
Ozioma F. Nwabor   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy